A phase 1 study to assess the mass balance, pharmacokinetics, metabolism, and excretion of GSBR-1290, containing a microtracer dose of [14C] GSBR-1290, in healthy participants
Phase 1
Completed
- Conditions
- Not applicable - Healthy volonteers
- Registration Number
- 2024-512578-83-00
- Lead Sponsor
- Structure Therapeutics Inc., Structure Therapeutics Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ended
- Sex
- Not specified
- Target Recruitment
- 8
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Not specified
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Pharmaceutical Research Associates Group B.V.
🇳🇱Groningen, Netherlands
Pharmaceutical Research Associates Group B.V.🇳🇱Groningen, NetherlandsSalah HadiSite contact+31504022524salah.hadi@iconplc.com